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ABSTRACT
Background. The Hermine study observed the use of
trastuzumab for metastatic breast cancer (MBC) in
routine practice, including patients who received tras-
tuzumab treatment beyond progression (TBP).
Patients and Methods. The study observed 623 pa-
tients for >2 years. Treatment was given according to
oncologists’ normal clinical practices. Endpoints in-
cluded duration of treatment, efficacy, and cardiac
safety. The TBP subanalysis compared overall survival
(OS)in177patientswhoreceivedfirst-linetrastuzumab
and either continued trastuzumab for >30 days follow-
ing progression or stopped at or before progression.
Results. The median treatment duration was 13.3
months. In the first-, second-, and third-line or beyond
treatment groups, the median time to progression
(TTP) were 10.3 months, 9.0 months, and 6.3 months,
and the median OS times were 30.3 months, 27.1
months, and 23.2 months, respectively. Heart failure
Correspondence: Jean-Marc Extra, M.D., Institut Paoli-Calmettes, Oncologie Médicale, 232 Boulevard de St Marguerite, 13273 Mar-
seille Cedex 9, France. Telephone: 33-0-4-91-22-35-37; Fax: 33-0-4-91-22-35-60; e-mail: extrajm@marseille.fnclcc.fr Received Feb-
ruary 20, 2009; accepted for publication May 17, 2010; first published online in The Oncologist Express on July 29, 2010; available online
without subscription through the open access option. ©AlphaMed Press 1083-7159/2010/$30.00/0 doi: 10.1634/theoncologist.2009-0029
The Oncologist
®
Academia–Pharma Intersect: Breast Cancer
The Oncologist 2010;15:799–809 www.TheOncologist.comwas observed in 2.6% of patients, although no cardiac-
associated deaths occurred. In the TBP subanalysis, the
median OS duration from treatment initiation and time
of disease progression were longer in patients who con-
tinued receiving trastuzumab TBP (>27.8 months and
21.3 months, respectively) than in those who stopped
(16.8 months and 4.6 months, respectively). However,
the groups were not completely comparable, because
patients who continued trastuzumab TBP had better
prognoses at treatment initiation. The median TTP was
longer in patients who continued trastuzumab TBP
(10.2 months) than in those who stopped (7.1 months).
Conclusion. The Hermine findings confirm that the
pivotal trials of first-line trastuzumab treatment in
MBC patients are applicable in clinical practice. The
subanalysissuggeststhattrastuzumabTBPoffersasur-
vival benefit to MBC patients treated with first-line
trastuzumab. The Oncologist 2010;15:799–809
INTRODUCTION
The survival benefit from trastuzumab (Herceptin;F .
Hoffmann-La Roche Ltd, Basel, Switzerland), a recom-
binant monoclonal antibody, has been well established
in clinical trials of patients with early breast cancer and
metastatic breast cancer (MBC) that overexpress human
epidermal growth factor receptor (HER)-2 [1–5]. Trastu-
zumab-based treatment is the standard of care for HER-2

MBC patients [6], but MBC remains essentially incurable
and patients ultimately experience progressive disease [1].
The Hermine study, an observational study conducted
in France, was designed to evaluate outcomes in patients
with MBC who received trastuzumab treatment in routine
clinical practice. With 600 patients, the Hermine study is
one of the largest studies of trastuzumab in MBC. Because
trastuzumab has also been associated with cardiac events,
particularly in patients with prior exposure to anthracy-
clines [7, 8], the Hermine study also aimed to examine the
cardiac safety of trastuzumab in patients treated in routine
practice.
This paper reports data collected for the overall study
population, as well as according to the initial line of trastu-
zumab treatment. A subanalysis focused on patients who
continued to receive trastuzumab after progression, pre-
senting an opportunity to evaluate the efficacy of trastu-
zumab treatment beyond progression (TBP) in the largest
patient series to date (n  177).
METHODS
Study Design and Patients
The Hermine trial was a French multicenter, pharmacoepi-
demiologic, retrospective and prospective, observational
cohortstudythatwasmanagedbyanindependentscientific
committee that included three breast cancer specialists, a
pathologist, and an epidemiologist. In accordance with
French legislation regarding noninterventional studies, the
study protocol was validated by the Comité Consultatif sur
le Traitement de l’Information en Matière de Recherche
dans le Domaine de la Santé and approved by the Commis-
sion Nationale de l’Informatique et des Libertés, which
guarantees patient confidentiality.
Participating oncologists were drawn from universities,
hospitals,andcancertreatmentcentersacrossFrance.Inthe
absence of a national breast cancer oncologist database, the
names of oncology specialists were obtained from a data-
base managed by the sponsor (Roche SAS, Neuilly-sur-
Seine, France). This database included 250 breast cancer
specialists already prescribing trastuzumab. Specialists
from the database were selected at random and invited to
retrospectivelyincludeallwomenaged18yearswhohad
first received trastuzumab for MBC between January 1 and
December 31, 2002; patients were identified via pharmacy
records. All patients were informed of the study objectives.
Once in the study, patients continued to be treated and as-
sessedinaccordancewiththeironcologists’normalclinical
practices, with trastuzumab administered as an i.v. infusion
either weekly or 3-weekly.
One-year follow-up data were collected retrospectively
between November 2003 and April 2004. Final data (min-
imum patient follow-up 2 years) were collected prospec-
tively in March 2005. All data were collected from patient
filesandreviewedbytheindependentscientificcommittee;
any questions arising from this review were sent to the ap-
propriate physicians for clarification.
AsubanalysisoftheHerminestudyexaminedoutcomes
in patients with MBC treated initially with trastuzumab as
first-line therapy who subsequently experienced disease
progression and either continued trastuzumab TBP (for
30 days) or discontinued trastuzumab within 30 days of
progression.
Study Endpoints
The primary endpoint was treatment duration with trastu-
zumab (defined as the time between first and last infusion,
including beyond disease progression). Secondary end-
points included: combination therapies with trastuzumab;
frequency of, and reasons for, stopping trastuzumab; time
to progression (TTP); sites of disease progression; and
overall survival (OS). Cardiac safety was also a secondary
800 Trastuzumab After Disease Progression for MBCendpoint and included available left ventricular ejection
fraction (LVEF) assessments and documented cardiac
events. An LVEF 50% was considered normal.
The TBP subanalysis endpoints included duration of
trastuzumab treatment, TTP from initiation of treatment,
andOSfrominitiationoftrastuzumabandfromdateoffirst
progression.
Statistical Methods
In order to assess trastuzumab treatment duration to an ac-
curacyof15days(usingatwo-sided95%confidenceinter-
val [CI]), it was calculated that 454 patients would be
required.Thiswasbasedontheassumptionofameantreat-
mentdurationof240days,withastandarddeviationof163
days, as seen in a previous trial [5]. Allowing for 10% in-
complete data, 500 patients were required. Each oncologist
was expected to include at least five patients; it was as-
sumed that 10% of oncologists would not complete the
study, so 110 specialists were invited to enroll patients.
Statistical analyses were performed using SAS, version
8.2 (SAS Institute Inc., Cary, NC). Time-to-event data
(treatment duration, TTP, OS) were analyzed using the
Kaplan–Meier method both for the overall population and
according to the initial line of trastuzumab treatment (first,
second,andthirdorbeyond).TTPwasdefinedastimefrom
initiation of trastuzumab to progression or disease-related
death, and the OS time was defined as the time from initia-
tion of treatment to death resulting from any cause. For pa-
tients without progression or disease-related death at the
end of the follow-up, data were recorded on the date of the
last known follow-up visit. The impact of prognostic fac-
tors—including patient demographics, tumor characteris-
tics (hormone-receptor status, Scarff-Bloom-Richardson
histologicgrade),MBChistory(numberofmetastaticsites,
site localization, and disease-free interval, defined as time
from breast cancer diagnosis to appearance of metastatic
disease), mode of trastuzumab administration (mono-
therapy versus combination therapy), and previous treat-
ment lines for metastatic disease on TTP and OS—was
analyzed in an exploratory analysis using a Cox regression
model. Identified factors are presented with a hazard ratio
(HR) and 95% CI. All analyses were performed using a
two-sided significance level of 5%.
TheTBPsubanalysiscompareddurationoftrastuzumab
treatment, TTP from initiation of treatment, and OS using a
log-rank test. An exploratory analysis was performed, as in
the whole-population analysis, to identify potential inde-
pendent prognostic factors for OS.
The analysis of cardiac safety, evaluated by LVEF as-
sessments, was descriptive only.
RESULTS
Patient Characteristics
Overall, 116 oncologists agreed to participate in the study
and 102 included at least one patient. In total, 643 patients
were registered and, of these, 623 were evaluable (Fig. 1).
Twenty patients were excluded because of protocol devia-
tions:metastaticstatusnotconfirmed(n17),cancerother
than breast (n  1), missing file (n  1), and treatment
initiated before 2002 (n  1).
Patient characteristics are summarized in Table 1.
HER-2statuswasassessedlocallybyimmunohistochemis-
try(IHC)for599(96%)patients;93%hadIHC3tumors.
Fluorescence in situ hybridization (FISH) was used alone
for nine patients and in addition to IHC in six; overall, 12
patients had HER-2–amplified tumors as assessed by FISH
(FISH
).
The median time since diagnosis of the primary breast
cancer and start of trastuzumab treatment was 2.9 years
(range, 0–36.1); 20% of patients had MBC at first diagno-
sis.Prioranthracyclinetreatmenthadbeenreceivedby84%
of the overall population.
Trastuzumab was initially prescribed as first-, second-,
or third-line or beyond treatment for MBC in 221 (36%),
138 (22%), and 243 (39%) patients, respectively (Table 2).
Information on the number of previous treatment lines was
missing for 21 patients (3%).
Approximately one quarter of the patients had a history
of cardiac problems before starting trastuzumab treatment,
including arterial hypertension (17.1% of patients). Base-
line LVEF was assessed in 357 patients (57%). The median
LVEF was 63% (range, 23%–88%), with 96% of patients
having a normal LVEF (50%); 2% had an LVEF 40%.
A baseline electrocardiogram was assessed in 259 patients
(44%) and was abnormal in 14 patients. Of these, two pre-
sented with ischemia, six with dysrhythmia, and six with
conductive heart disorders.
TBP Subanalysis
From the total Hermine cohort, 177 patients experienced
disease progression after receiving first-line trastuzumab
andwereevaluableintheTBPsubanalysis(medianfollow-
up, 24.4 months) (Fig. 1); 107 patients continued trastu-
zumab for 30 days beyond first progression and 70
stopped therapy before progression or within 30 days after
disease progression.
Patient characteristics are presented in Table 2. More
grade 3 tumors, a shorter disease-free interval, more vis-
ceral metastases, and less adjuvant hormonal therapy were
observed in patients who did not receive trastuzumab after
first progression. Patients who had brain metastases at the
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groups. Patients receiving trastuzumab TBP had a longer
medianfollow-up(27.8months)thanthoseforwhomtreat-
ment was stopped at progression (16.9 months) (Table 2).
Exposure to Trastuzumab
Most patients (89%) received once-weekly trastuzumab
(Table 2). Trastuzumab was given as part of a combination
regimen in 94% of patients, generally with chemotherapy
(Table 3). Trastuzumab was combined with hormonal ther-
apy (with or without chemotherapy) in 22% of patients
(14.5%, 26.1%, and 23.5% of patients on first-, second-,
and third-line treatment, respectively).
Overall, the median treatment duration with trastuzumab
was 13.3 months (range, 0–37.7 months). The median treat-
ment durations in patients who initially received trastuzumab
first line, second line, and third line or beyond were 16.1
months, 15.8 months, and 8.9 months, respectively.
Trastuzumab was temporarily discontinued on 411 oc-
casions in 284 (46.1%) of the 616 patients for whom these
datawererecorded,foramediandurationof25days(range,
8–644 days). After a median follow-up of 22.9 months
(range, 0.1–37.7 months), 478 patients had definitively
stopped trastuzumab, a rate of 75% at 2 years. Reasons for
stopping trastuzumab within 1 year of initiation (n  369) in-
cludedclinicalprogression(n212),physiciandecision(n
70), cardiac event (n  37), and/or patient request (n  13).
Efficacy
TTP
During follow-up, 545 progression events were recorded.
Documentedsitesoffirstprogressionafterinitiationoftras-
tuzumab in these patients were liver (33%), central nervous
system (CNS; 28%), bone (25%), lung (17%), local-re-
gional (9%), and/or pleura (6%).
The median TTP was 8.6 months (95% CI, 7.6–9.3
months) (Fig. 2A) for the overall population and 10.3
months, 9.0 months, and 6.3 months, respectively, in the
subgroups initially treated with trastuzumab first line, sec-
ond line, and third line or beyond.
OS
There were 336 deaths, with a median OS time of 25.9
months (95% CI, 23.4–28.9 months) (Fig. 2B). The 2-year
OS estimates varied with line of initial trastuzumab treat-
ment:58%,55%,and48%forfirst,second,andthirdlineor
beyond, respectively. The corresponding median OS times
were 30.3 months, 27.1 months, and 23.2 months, respec-
tively.
In an exploratory analysis, significant independent pre-
dictors of OS were: number of metastatic sites at treatment
initiation (three or more: HR, 1.49; 95% CI, 1.16–1.91),
mode of trastuzumab administration (combination: HR,
0.34; 95% CI, 0.23–0.51), CNS metastases at trastuzumab
initiation (HR, 2.94; 95% CI, 2.02–4.28), visceral non-
CNSmetastasesattrastuzumabinitiation(presenceoflung/
liver metastases: HR, 1.64; 95% CI, 1.26–2.13), disease-
free interval from breast cancer diagnosis to appearance of
metastasis (24 months: HR, 0.59; 95% CI, 0.48–0.74),
and number of previous treatment lines for MBC (more
than one: HR, 1.15; 95% CI, 1.01–1.31).
TBP Subanalysis
The first-line median TTP was longer for patients treated
with trastuzumab after progression (10.2 months; 95% CI,
Figure 1. Consolidated Standards of Reporting Trials diagram of patients in the Hermine study.
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withdrawn at progression (7.1 months; 95% CI, 6.1, 7.9
months) (log-rank test p  .0215). Site of first progression
in patients treated with first-line trastuzumab included the
liver (34%), CNS (34%), bone (24%), and lungs (17%).
When analyzed from the initiation of trastuzumab, the
OS time was significantly longer in patients who continued
to receive trastuzumab treatment after progression than in
patients whose treatment was withdrawn at progression
(p  .001) (Fig. 3A), with a median OS time for patients
who continued trastuzumab not reached after 27.8 months’
follow-upandamedianOStimeof16.8monthsforpatients
whostoppedtrastuzumabatprogression.Likewise,patients
who continued trastuzumab after progression had a signif-
icantly longer median OS time from date of first progres-
sion (21.3 months) than patients whose trastuzumab
treatment was stopped at progression (4.6 months) (p 
.0001) (Fig. 3B).
Exploratory subgroup analyses showed that continuing
trastuzumab TBP was an independent prognostic factor for
OS after first-line trastuzumab in MBC (Fig. 4).
Cardiac Safety
During the first year of follow-up, 468 patients (75%) un-
derwent at least one LVEF assessment. Of these, 23% had
anabnormalLVEF,with4%havingnLVEF40%.At1–2
years of follow-up, 192 patients (31%) had an LVEF as-
sessment. The median LVEF in those patients was 62%
(range, 26%–82%), with 12% having an abnormal value.
Fifty-four patients (9%) experienced at least one symp-
tomatic cardiac adverse event (range, 1–3) during follow-
up, 39 (6%) during trastuzumab treatment. Of these
patients, 49 had previously received treatment with anthra-
Table 1. Baseline patient and disease characteristics of
the whole Hermine cohort
Characteristic
Total
(n  623)
Median (range) age, yrs (n  623) 54 (25–84)
HER-2 status (n  599)
a
IHC 3, n (%) 558 (93)
IHC 2, n (%) 26 (4)
IHC 0–1, n (%) 6 (1)
IHC not classified, n (%) 9 (2)
FISH
, n 12
FISH
, n 3
Hormone-receptor status, crossed results
(n  561), n (%)
ER
PgR
 186 (33)
ER
PgR
 90 (16)
ER
PgR
 34 (6)
ER
PgR
 251 (45)
Histologic type of primary tumor (n  617),
n (%)
Ductal carcinoma 559 (90.6)
Lobular carcinoma 30 (4.9)
Ductal and lobular (mixed) carcinoma 19 (3.1)
Other 9 (1.2)
Histologic grade: Scarff-Bloom-Richardson
(n  561), n (%)
1 25 (5)
2 208 (37)
3 316 (56)
Not classified 12 (2)
Type of previous treatment (n  623), n (%)
Surgery 550 (88)
Radiotherapy 506 (82)
Hormonal therapy 361 (58)
Chemotherapy 560 (90)
Median (range) disease-free interval, mos 25 (0–411)
Metastatic sites before trastuzumab
initiation (n  621), n (range)
2 (1–8)
3, n (%) 459 (74)
3, n (%) 162 (26)
Disease sites location, n (%)
Visceral
b 441 (71)
Liver 324 (52)
Bone 268 (43)
Lung 186 (30)
Skin 108 (17)
Pleura 65 (11)
CNS 40 (6)
(continued)
Table 1. (Continued)
Characteristic
Total
(n  623)
Cardiac status, n (%)
History of cardiac disorders 141 (23)
Hypertension 103 (17)
Ischemic heart disease 8 (2)
Heart failure 9 (2)
Coronary artery disease 4 (1)
aHER-2 status assessed by both IHC and FISH in six
cases.
bLiver and/or lung and/or CNS.
Abbreviations: CNS, central nervous system; ER,
estrogen receptor; FISH, fluorescence in situ
hybridization; HER-2, human epidermal growth factor
receptor 2; IHC, immunohistochemistry; PgR,
progesterone receptor.
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cardiovascularriskfactors(hypertension,tobaccouse,fam-
ily history, diabetes, and hyperlipidemia). Of the 65 re-
corded events, the most common were heart failure (n 
16) and tachycardia/other arrhythmia (n  11). New York
Heart Association (NYHA) classification of heart failure
was recorded for seven patients: I, n  2; II, n  3; and III,
n2.Overall,45ofthesymptomaticeventsrequiredmed-
ical treatment and 16 required hospitalization. The cardiac
eventsresolvedin26cases,improvedin21cases,andwere
unchanged/outcome unrecorded in the remaining 18 cases.
No cardiac-related deaths occurred.
TBP Subanalysis
Prior to starting trastuzumab treatment, LVEF measure-
ments were collected in 96 patients (54%) in this subgroup,
with a median value of 65% (range, 23%–81%). Six pa-
tients (7%) had an LVEF 50% and, of these, five had an
LVEF 40%.
Duringthefirstyearoffollow-up,LVEFmeasurements
were collected from 136 patients in this subgroup. LVEF
was50%in12.7%ofpatientsreceivingtrastuzumabafter
disease progression and in 24.4% of those who stopped
trastuzumab after disease progression. The corresponding
incidencesofLVEFdeclineto40%were2.6%and7.3%.
Table 2. Characteristics of patients at initiation of trastuzumab treatment
Characteristic
First-line
trastuzumab
Second-line
trastuzumab
Third-line
or beyond
trastuzumab
First-line trastuzumab with
disease progression
Trastuzumab
stopped >30
days beyond
progression
Trastuzumab
stopped at or
prior to
progression
Patients, n 221 138 243 107 70
Mean age, yrs 54 56 56 51 57
HER-2 status, n (%) 199 (96) 122 (92) 218 (91) 97 (96) 64 (96)
IHC 3
Hormone-receptor status, n (%)
ER and/or PgR positive 84 (41) 61 (49) 154 (71) 40 (41) 28 (41)
Histology: Scarff-Bloom-Richardson
grade, n (%)
2 61 (31) 44 (35) 95 (43) 38 (39) 12 (19)
3 129 (65) 73 (58) 108 (49) 57 (58) 46 (74)
Mean (range) disease-free interval,
a
yrs
2.7 (0–16) 2.4 (0–24)
24 mos, n (%) 114 (54) 68 (50) 109 (46) 60 (56) 44 (64)
24 mos, n (%) 96 (46) 69 (50) 129 (54) 47 (44) 25 (36)
Type of previous treatment, n (%)
Surgery 198 (90) 122 (88) 212 (87) 98 (92) 61 (88)
Adjuvant hormonal therapy 70 (32) 48 (35) 79 (33) 39 (36) 18 (26)
Adjuvant chemotherapy 135 (61) 82 (59) 106 (44) 70 (65) 41 (59)
Anthracyclines 160 (86) 116 (91) 226 (95) 76 (88) 55 (86)
Disease sites before trastuzumab
initiation
Median (range) sites, n 2 (1–5) 2 (1–5) 2 (1–8) 2 (1–5) 2 (1–5)
Location, n (%)
Visceral
b 146 (66) 102 (75) 179 (74) 69 (65) 57 (83)
CNS 13 (6) 8 (6) 18 (7) 1 (1) 1 (1)
Median (range) duration of
follow-up, months
24.4 (0.1–37.7) NA NA 27.8 (3.9–37.7) 16.9 (0.1–35.1)
aDefined as time from breast cancer diagnosis to metastatic disease.
bLiver and/or lung and/or CNS.
Abbreviations: CNS, central nervous system; ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2;
IHC, immunohistochemistry; NA, not available; PgR, progesterone receptor.
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and 21.7% of patients, respectively.
One patient from each of the two treatment groups de-
veloped congestive heart failure.
DISCUSSION
The Hermine study was designed to evaluate use, efficacy,
and safety outcomes with trastuzumab under noncon-
trolled, “real life” conditions with an unselected population
of patients with HER-2
 MBC. In this pharmacoepidemio-
logic cohort of 623 patients initially treated with trastu-
zumab first line, second line, and third line or beyond, the
median TTP was 8.6 months and median OS duration was
25.9months.ResultsforTTPandOSseemtoshowclinical
benefit irrespective of initial line of treatment, although the
greatest benefits occurred in patients treated first line.
InthosepatientstreatedfirstlineforMBC,theTTPwas
10.3 months and the OS time was 30.3 months, outcomes
thatareatleastcomparablewiththoseinthepivotaltrialsof
first-line trastuzumab plus a taxane for HER-2
 MBC
(TTP, 7.1 months and 11.7 months, respectively; OS, 25.0
months and 31.2 months, respectively) [4, 9]. Thus, the
clinical benefits achieved with first-line trastuzumab for
HER-2
 MBC in the controlled trial setting appear to be
achieved in daily clinical practice.
The 2-year follow-up of patients who received first-line
trastuzumabinroutinepracticeallowedinvestigationofthe
benefit of continuing trastuzumab beyond disease progres-
sion. Those who continued with trastuzumab TBP had a
significantly longer median OS time from the date of that
progression than those who stopped trastuzumab at pro-
gression (21.3 months versus 4.6 months; p  .001). A sig-
nificant difference in terms of OS was also apparent from
the date of initiation of trastuzumab therapy. Despite the
imbalance in prognostic factors between the two groups, an
exploratory subgroup analysis identified continuing trastu-
zumabTBPasanindependentprognosticsurvivalfactoraf-
ter first-line trastuzumab treatment for MBC, suggesting
that continuing trastuzumab TBP provides significant clin-
ical benefit.
OS benefits were also associated with continuing tras-
tuzumab TBP in Hermine patients who had initially re-
ceived trastuzumab as second-line therapy for MBC (n 
121) [10].
ThefindingsoftheTBPsubanalysisreflectthoseofpre-
vious smaller studies and are supported by studies in
HER-2
humanxenograftmodels[11].Numerouscompar-
ative and noncomparative studies have reported tumor re-
sponseratesof11%–50%toasecondtrastuzumabregimen,
indicating that HER-2
 breast cancer is not refractory to
further trastuzumab therapy after first progression [12–18].
In retrospective case analyses, a median TTP after a second
trastuzumab-based regimen of 5–8 months has been re-
ported [12–15, 19, 20]. In one case series [17], the OS time
from the date of diagnosis of MBC was 62.4 months in pa-
tients who received at least two trastuzumab-based regi-
mens (n  23), compared with 38.5 months in those who
received one regimen only (n  113) (p  .01). In contrast,
no difference in OS (calculated from the date of trastu-
zumab initiation) was documented in an Italian case series
in which 40 patients had received trastuzumab TBP and 71
patients had stopped trastuzumab at progression (median,
30.1monthsand30.2months,respectively)[15].However,
in our study, an imbalance was reported in the chemother-
apy/hormonal therapy regimens between the two treatment
groups.
Results from a phase III randomized study (German
BreastGroup[GBG]-26)comparingtrastuzumabandcape-
citabine with capecitabine alone in 156 patients who had
progressed during trastuzumab therapy also support our
findings that trastuzumab is effective when continued as
TBP [21]. Treatment with trastuzumab plus capecitabine
doubledtheoverallresponserate(48.1%versus27.0%)and
TTP (8.2 months versus 5.6 months; p  .034) compared
Table 3. Trastuzumab treatment of the whole
Hermine cohort
Trastuzumab schedule
Median (range) loading dose, mg/kg 4 (1.4–9)
Administration frequency (n  612), n (%)
Once weekly 547 (89)
3-weekly 57 (9)
Other 8 (2)
Trastuzumab regimen (n  623), n (%)
Monotherapy 37 (6)
Combination therapy 586 (94)
Trastuzumab combination therapy
(n  623),
a n (%) with chemotherapy
578 (93)
Paclitaxel 377 (61)
Docetaxel 154 (25)
Vinorelbine 215 (35)
Capecitabine 55 (9)
Platinum salts 44 (7)
Anthracyclines 12 (2)
With hormonal therapy 136 (22)
Aromatase inhibitors 125 (20)
Tamoxifen 10 (2)
aPatients could have received more than drug in
combination with trastuzumab during the minimum
follow-up of 2 years.
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pected toxicity [21].
AtthetimeoftheHerminestudy,therewerenoongoing
trials of lapatinib in France. However, second-line treat-
ment with other HER-2–targeting therapies for advanced
breast cancer has now been investigated in patients who
progressed on first-line trastuzumab. In a phase III, ran-
domized, open-label study, patients with HER-2
 locally
advanced breast cancer or MBC, previously treated with an
anthracycline, a taxane, and trastuzumab in the metastatic
Figure 2. Kaplan–Meier curve of time to progression (A) and overall survival (B) in the overall study population. Date of death
was not recorded in five patients.
Figure 3. Kaplan–Meier plot comparing OS data from patients who continued trastuzumab beyond progression with that of
patients who stopped trastuzumab treatment at or prior to progression from initiation of trastuzumab (A) and date of progression
(B).
Abbreviations: CI, confidence interval; OS, overall survival.
Figure 4. Independent prognostic survival factors for first-line trastuzumab in metastatic breast cancer.
Abbreviations: CI, confidence interval; ER, estrogen receptor; PgR, progesterone receptor.
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alone [22]. The primary endpoint of TTP was shorter with
both lapatinib plus capecitabine (6.2 months) and capecit-
abine alone (4.3 months) than was observed in the Hermine
study (10.2 months for patients receiving trastuzumab after
progression and 7.1 months for patients who stopped tras-
tuzumab at progression), but a cross-study comparison is
not appropriate because of methodologic differences. The
availabilityoflapatinibraisesquestionsaboutthemostsuit-
able agent to maintain HER-2 suppression following dis-
ease progression, and this should be investigated in a
randomized study. Preclinical evidence demonstrates that
trastuzumab retains antitumor activity beyond progression
as a result of continued suppression of HER-2 and activa-
tion of the immune system by antibody-dependent cellular
cytotoxicity [23–25]. In addition, recent clinical trials have
also demonstrated the benefit of continuing trastuzumab
beyond disease progression [21, 26].
Differing protocols with regard to the monitoring, re-
cording, and analysis of cardiac events make cross-study
comparisons of cardiac safety problematic. However, the
incidence of heart failure (2.6%) for patients enrolled in the
Hermine study was similar to that in the pivotal first-line
MBC M77001 trial evaluating trastuzumab plus docetaxel,
which carefully screened patients for cardiac dysfunction
prior to enrollment [4]. The incidence of symptomatic car-
diac events in the Hermine study was also much lower than
in the H0648g trial [5], despite 84% of patients having pre-
viously received anthracyclines. Furthermore, the majority
of patients with symptomatic cardiac events subsequently
recoveredorimproved.Inanotherretrospectiveanalysis,of
patients who received trastuzumab for HER-2
 MBC (n 
173; median treatment duration, 21.3 months; range, 11.6–
77.6 months), NYHA cardiac dysfunction (class I–IV) was
reported in 31% of patients, compared with only 1.1% of
patients in the Hermine study (class I–III; no class IV
NYHA cardiac failure was reported) [27]. This difference
maybearesultofstandardizedcardiacmonitoring,because
thestudywasconductedatonlyonecenter,andemphasizes
theimportanceofcarefulcardiacassessment.LVEFassess-
ments confirmed that trastuzumab was also well tolerated
when given beyond progression.
HER-2 overexpression is a recognized risk factor for
CNS metastases [28]; however, patients with HER-2
 dis-
ease with CNS metastases treated with trastuzumab have a
better survival outcome than patients with HER-2
 disease
and CNS metastases [29, 30]. Emerging evidence suggests
that patients with CNS metastases should continue to re-
ceive trastuzumab along with established therapies for the
CNS metastases [31].
Pharmacoepidemiologic studies such as the Hermine
study have limitations and inherent biases, which were
identifiedbeforethestartofthestudy.Thephysician-selec-
tion and patient-inclusion criteria were chosen to minimize
selection bias. After completion, the study design was re-
checked to ensure the study was adequately controlled.
Random selection of physicians from a comprehensive da-
tabase of breast cancer specialists ensured that the oncolo-
gists participating in the study were representative of the
database and the French oncologist population as a whole,
in both geographic distribution and type of establishment.
The selection criteria for patients also ensured that the Her-
mine study accurately reflected the true clinical use of tras-
tuzumab in a heterogeneous population of breast cancer
patients across France. Furthermore, patients were selected
for inclusion after the date of first treatment. Patients were
identified according to pharmacy records rather than by
physician recommendation; 93% of eligible patients were
actually registered in the study.
In the subanalysis of patients from the Hermine cohort
who progressed after receiving first-line trastuzumab, there
were some imbalances in terms of disease characteristics
between patients who continued trastuzumab TBP and
those who did not. Those who continued trastuzumab TBP
had a better prognosis at treatment initiation, with the pa-
tients having lower Scarff-Bloom-Richardson grading, a
longer disease-free interval, fewer visceral metastases, and
more adjuvant hormonal therapy. This imbalance in prog-
nosis between the groups is reflected in both the median
TTP (10.2 months versus 7.1 months) and the median du-
ration of treatment prior to disease progression (10.1
monthsversus6.1months).TheTTPresultsintheHermine
study suggest that the patients who continued trastuzumab
TBP may have belonged to a population with a more favor-
able prognosis than those who stopped trastuzumab at pro-
gression. However, it should be noted that the randomized
phase III study GBG-26 showed similar TTP results for
continued trastuzumab TBP [21].
CONCLUSIONS
In this large, observational study, the median trastuzumab
treatment duration was 13.3 months. Trastuzumab com-
bined with various chemotherapy and/or hormonal therapy
options for MBC was associated with a TTP approaching 9
months and an OS time 2 years, despite 60% of the co-
hort receiving trastuzumab initially as second-line therapy
or beyond.
The subanalysis of patients who progressed after first-
linetrastuzumabsuggeststhatcontinuingtrastuzumabTBP
offers clinical benefit to patients with HER-2
 MBC
treated initially with first-line trastuzumab. When calcu-
lated from the date of treatment initiation, the median OS
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www.TheOncologist.comtime had not been reached after a follow-up of 27.8 months
in patients who continued trastuzumab beyond first pro-
gression, compared with a median OS time of 16.8 months
inpatientswhostoppedtrastuzumabatdiseaseprogression.
A significantly longer median OS time (21.3 months) was
also reached in those patients, compared with patients who
stopped trastuzumab at disease progression (4.6 months),
when assessed from the date of first progression.
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